<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347554</url>
  </required_header>
  <id_info>
    <org_study_id>EVZT_2.0</org_study_id>
    <nct_id>NCT01347554</nct_id>
  </id_info>
  <brief_title>Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction</brief_title>
  <acronym>EVERZOTA</acronym>
  <official_title>Comparison of the Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Stent for Coronary Lesions in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the previous data regarding the efficacy of the everolimus-eluting stent (EES) was
      derived from studies comparing EES with bare metal stent (BMS) or EES with paclitaxel-eluting
      (PES). Although sirolimus-eluting stents (SES) have been shown to be the most efficacious
      drug regarding inhibition of neointima and late loss, there have been no previous head to
      head comparisons between EES and zotarolimus-eluting stent (ZES). Both everolimus and
      sirolimus are macrocyclic lactones that target the mTOR (mammalian target of rapamycin) to
      reduce vascular smooth muscle proliferation after vessel injury and therefore in principle
      may show similar results after stenting in humans. Data pooled from the EES arm that received
      follow up angiography in the SPIRIT III trial and the SES arm in the SIRIUS trial show
      similar rates of binary restenosis and late loss. However, the stent and polymer platform is
      not the same between the EES and ZES and it is reported that the EES system has the thinnest
      stent + polymer thickness (88.6um) of all of the previously KFDA-approved drug-eluting stent
      (DES). In addition, there are no data available on the efficacy of the EES and ZES in &quot;real
      world&quot; lesions other than the selected lesions studied in the previous trials, such as acute
      myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous randomized trials have shown the efficacy of a slow-release polymeric
      sirolimus-eluting stent (CYPHER, Cordis, Warren, NJ, USA), paclitaxel-eluting stent (TAXUS,
      Boston Scientific, Natick, MA, USA), and zotarolimus-eluting stent (Endeavor, Medtronic,
      Minneapolis, MN, USA) over bare metal stents in reducing neointimal hyperplasia, late luminal
      loss, and angiographic restenosis leading to decreased target lesion revascularization. The
      everolimus-eluting stent (XIENCE V, Abott Vascular, Santa Clara, CA, USA, PROMUS, Boston
      Scientific, Natick, MA, USA) is a newly developed drug eluting stent using the MULTILINK
      VISION® stent platform combined with the drug everolimus contained in a polymer coating.

      In the first-in-man SPIRIT First clinical trial, XIENCE V showed a significant benefit over
      the bare metal VISION stent. Compared with late loss of 0.85 ± 0.36mm in the VISION arm,
      XIENCE V reduced late loss by 88% (0.10 ± 0.23mm). Also the clinical safety of XIENCE V was
      confirmed with a 6-month MACE rate of 7.7%. In the SPIRIT II clinical trial, which compared
      the efficacy and safety of the XIENCE V stent versus the TAXUS PECSS stent, the primary
      endpoint was met showing a non-inferiority of the XIENCE V compared with the TAXUS regarding
      in-stent late loss at 180 days. Actually, XIENCE V was superior to TAXUS and reduced in-stent
      late loss by 72% from a mean of 0.36 mm to 0.11 mm. In addition, analysis of other key
      clinical endpoints showed a lower rate of ischemia driven MACE (2.7% vs. 6.5% for XIENCE V
      vs. TAXUS) and protocol-defined stent thrombosis (0.5% vs. 1.3% for XIENCE V vs. TAXUS). The
      lower rate of ischemia driven MACE at 180 days was sustained through 1 year and there were no
      new instances of late stent thrombosis in either group up to 1 year.

      The SPIRIT III RCT was a prospective, 2:1 randomized, active-controlled, single blinded,
      parallel, multi-center clinical evaluation of the XIENCE V Everolimus Eluting Coronary Stent
      System (XIENCE V EECSS) compared to TAXUS Paclitaxel Eluting Coronary Stent System (TAXUS
      PECSS) in the treatment of up to two de novo lesions. This pivotal clinical trial was
      designed to demonstrate the non-inferiority of the XIENCE V EECSS to the TAXUS PECSS.
      Patients were randomized 2:1 to XIENCE V or TAXUS and the primary endpoint was in-segment
      late loss at 240 days. The results showed a mean in-segment late loss of 0.14mm for XIENCE V
      and 0.28 mm for TAXUS (p&lt;0.001 for non-inferiority, p=0.0037 for superiority). The secondary
      endpoint, which was ischemia-driven target vessel failure (TVF), was 7.6% for XIENCE V and
      9.7% for TAXUS, confirming the non-inferiority of XIENCE V. Furthermore, the rate of definite
      and probable stent thrombosis was 1.1% and 0.6% for XIENCE V and TAXUS, respectively.

      With a recent approval of new DES, zotarolimus-eluting stent (Endeavor, Medtronic,
      Minneapolis, MN), other comparison studies have been conducted to compare Endeavor
      zotarolimus-eluting stent with the sirolimus-eluting stent and paclitaxel-eluting stent.
      zotarolimus and sirolimus share some common structural and biological properties. In vitro
      data suggest that sirolimus and tetrazole containing rapamycin analogs have similar
      inhibitory effects in a mixed lymphocyte reaction assay. The ENDEAVOR clinical trials are
      currently in progress to evaluate a phosphoryl choline (PC)-coated zotarolimus-eluting
      stent(ZES) for the prevention of restenosis. The Endeavor zotarolimus-eluting stent utilizes
      a cobalt alloy balloon-expandable stent (Driver; Medtronic) with a geometry similar to the
      stainless steel stent used in this preliminary study (S7; Medtronic). The Endeavor ZES also
      employees a PC strut surface coating as the drug delivery reservoir with a dose of 10 g/mm of
      ABT-578. The Endeavor (ZES), however, differs from the stent used in this experimental study
      by the addition of a drug-free PC topcoat to serve as a diffusion barrier to retard drug
      release from the polymer reservoir. Angiographic analysis at 4 months in the 100-patient
      focal de novo lesion ENDEAVOR I feasibility study demonstrated a mean in-stent percent
      diameter stenosis of approximately 14% and a late lumen loss of 0.3 mm with a low frequency
      of target lesion revascularization (1%). The clinical outcomes from the ENDEAVOR II (1,500
      patients randomized to ABT-578 or bare metal stent) and the ENDEAVOR III (436 patients
      randomized 3:1 to ABT-578 or Cypher) trials as well as other ongoing studies showed efficacy
      of the PC-coated ABT-578-eluting stent. In ENDEAVOR III study, the Endeavor stent had larger
      late loss and higher binary restenosis in both the analysis segment and stented segment.

      Most of the previous data regarding the efficacy of the EES was derived from studies
      comparing EES with BMS or EES with PES. Although sirolimus eluting stents (SES) have been
      shown to be the most efficacious drug eluting stent regarding inhibition of neointima and
      late loss, there have been no previous head to head comparisons between EES and ZES. Both
      everolimus and sirolimus are macrocyclic lactones that target the mTOR (mammalian target of
      rapamycin) to reduce vascular smooth muscle proliferation after vessel injury and therefore
      in principle may show similar results after stenting in humans. Data pooled from the EES arm
      that received follow up angiography in the SPIRIT III trial and the SES arm in the SIRIUS
      trial show similar rates of binary restenosis and late loss. However, the stent and polymer
      platform is not the same between the EES and ZES and it is reported that the EES system has
      the thinnest stent + polymer thickness (88.6um) of all of the previously KFDA-approved DES.
      In addition, there are no data available on the efficacy of the EES and ZES in &quot;real world&quot;
      lesions other than the selected lesions studied in the previous trials, such as acute
      myocardial infarction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-oriented Composite Outcome</measure>
    <time_frame>Two year</time_frame>
    <description>defined as a composite of cardiac death, Myocardial infarction not clearly attributable to a nontarget vessel and target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device-oriented Composite Outcome</measure>
    <time_frame>Two years</time_frame>
    <description>defined as a composite of all-cause mortality, any MI (includes non-target vessel territory) and repeat revascularization (includes all target and non-target vessel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Two years</time_frame>
    <description>Definite and probable stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Bleeding</measure>
    <time_frame>Two year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">461</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Xience V stent group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endeavor resolute group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus eluting stent</intervention_name>
    <description>Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute</description>
    <arm_group_label>Xience V stent group</arm_group_label>
    <other_name>Xience V</other_name>
    <other_name>Promus or Promus element</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus eluting stent</intervention_name>
    <description>Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute</description>
    <arm_group_label>Endeavor resolute group</arm_group_label>
    <other_name>Endeavor resolute</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Chest pain duration more than 10 minutes

          -  At least on of the following criteria

          -  A. ECG change (T inversion, ST depression or ST elevation)

          -  B. Cardiac enzyme elevation more than upper normal limit

          -  Significant coronary artery stenosis (&gt;50% by visual estimate)

          -  The patient or guardian agrees to the study

        Exclusion Criteria:

          -  Stent thrombosis

          -  Left main disease

          -  Cardiogenic shock

          -  Cronic kidney disease or renal failure requiring hemodialysis

          -  History of bleeding diathesis or known coagulopathy

          -  Gastrointestinal or genitourinary bleeding within the prior 3 months

          -  History of major surgery within 2 months

          -  Planned surgery requiring cessation of clopidogrel within 12 months of percutaneous
             coronary intervention (PCI)

          -  Serious patients whose life expectancy &lt;1 year or severe infectious status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Hwan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Wonju College of Medicine; Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>September 23, 2014</results_first_submitted>
  <results_first_submitted_qc>September 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2014</results_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-eluting stent</keyword>
  <keyword>everolimus</keyword>
  <keyword>zotarolimus</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>cardiovascular diseases</keyword>
  <keyword>MACE</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between January 2009 and December 2010, we undertook a multicenter, prospective, randomized trial in 4 tertiary university hospitals.</recruitment_details>
      <pre_assignment_details>Patients with acute myocardial infarction were eligible if they had at least one lesion with a diameter stenosis of 50%or more. Before randomization, 3 patients withdrew consent and 18 patients did not meet inclusion criteria among 500 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Xience V Stent Group</title>
          <description>Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction</description>
        </group>
        <group group_id="P2">
          <title>Endeavor Resolute Group</title>
          <description>Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="242"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="230">Final TIMI flow grade 0 or 1 patients or failed PCI cases (N=7) were excluded.</participants>
                <participants group_id="P2" count="231">Final TIMI flow grade 0 or 1 patients or failed PCI cases (N=11) were excluded.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xience V Stent Group</title>
          <description>Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction</description>
        </group>
        <group group_id="B2">
          <title>Endeavor Resolute Group</title>
          <description>Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="461"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="12.8"/>
                    <measurement group_id="B2" value="64.5" spread="11.8"/>
                    <measurement group_id="B3" value="64.5" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Device-oriented Composite Outcome</title>
        <description>defined as a composite of cardiac death, Myocardial infarction not clearly attributable to a nontarget vessel and target lesion revascularization</description>
        <time_frame>Two year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xience V Stent Group</title>
            <description>Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction</description>
          </group>
          <group group_id="O2">
            <title>Endeavor Resolute Group</title>
            <description>Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction</description>
          </group>
        </group_list>
        <measure>
          <title>Device-oriented Composite Outcome</title>
          <description>defined as a composite of cardiac death, Myocardial infarction not clearly attributable to a nontarget vessel and target lesion revascularization</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device-oriented Composite Outcome</title>
        <description>defined as a composite of all-cause mortality, any MI (includes non-target vessel territory) and repeat revascularization (includes all target and non-target vessel)</description>
        <time_frame>Two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xience V Stent Group</title>
            <description>Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction</description>
          </group>
          <group group_id="O2">
            <title>Endeavor Resolute Group</title>
            <description>Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction</description>
          </group>
        </group_list>
        <measure>
          <title>Device-oriented Composite Outcome</title>
          <description>defined as a composite of all-cause mortality, any MI (includes non-target vessel territory) and repeat revascularization (includes all target and non-target vessel)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Definite and probable stent thrombosis</description>
        <time_frame>Two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xience V Stent Group</title>
            <description>Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction</description>
          </group>
          <group group_id="O2">
            <title>Endeavor Resolute Group</title>
            <description>Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Definite and probable stent thrombosis</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Bleeding</title>
        <time_frame>Two year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xience V Stent Group</title>
            <description>Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction</description>
          </group>
          <group group_id="O2">
            <title>Endeavor Resolute Group</title>
            <description>Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction</description>
          </group>
        </group_list>
        <measure>
          <title>Any Bleeding</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Xience V Stent Group</title>
          <description>Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction</description>
        </group>
        <group group_id="E2">
          <title>Endeavor Resolute Group</title>
          <description>Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively small number of sample size. Therefore, our result may be underpowerd. The incidence of clinical events were low. And we did not record the compliance of dual antiplatelet therapy for at least 1 year.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Seung-Hwan Lee</name_or_title>
      <organization>Yonsei University Wonju College of Medicine</organization>
      <phone>+82-33-741-0920</phone>
      <email>carshlee@yonsei.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

